Santini D.; Santoni M.; Conti A.; Procopio G.; Verzoni E.; Galli L.; di Lorenzo G.; De Giorgi U.; De Lisi D.; Nicodemo M.; Maruzzo M.; Massari F.; Buti S.; Altobelli E.; Biasco E.; Ricotta R.; Porta C.; Vincenzi B.; Papalia R.; Marchetti P.; Burattini L.; Berardi R.; Muto G.; Montironi R.; Cascinu S.; Tonini G., Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma, «ONCOTARGET», 2016, 7, pp. 33381 - 33390 [articolo]
Maines F.; Caffo O.; De Giorgi U.; Fratino L.; Lo Re G.; Zagonel V.; D'Angelo A.; Donini M.; Verderame F.; Ratta R.; Procopio G.; Campadelli E.; Massari F.; Gasparro D.; Ermacora P.; Messina C.; Giordano M.; Alesini D.; Basso U.; Fraccon A.P.; Vicario G.; Conteduca V.; Galligioni E., Safety and Clinical Outcomes of Abiraterone Acetate after Docetaxel in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme, «CLINICAL GENITOURINARY CANCER», 2016, 14, pp. 48 - 55 [articolo]
Lolli C.; Caffo O.; Scarpi E.; Aieta M.; Conteduca V.; Maines F.; Bianchi E.; Massari F.; Veccia A.; Chiuri V.E.; Facchini G.; De Giorgi U., Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone, «FRONTIERS IN PHARMACOLOGY», 2016, 7, Article number: 376, pp. 1 - 7 [articolo]
Lolli C.; Basso U.; Derosa L.; Scarpi E.; Sava T.; Santoni M.; Crabb S.J.; Massari F.; Aieta M.; Conteduca V.; Maruzzo M.; La Russa F.; Wheater M.; Berardi R.; Galli L.; De Giorgi U., Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib, «ONCOTARGET», 2016, 7, pp. 54564 - 54571 [articolo]
Modena A.; Massari F.; Ciccarese C.; Brunelli M.; Santoni M.; Montironi R.; Martignoni G.; Tortora G., Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: ‘Game Over’?, «TARGETED ONCOLOGY», 2016, 11, pp. 431 - 446 [articolo]
Ciccarese C; Brunelli M; Montironi R; Fiorentino M; Iacovelli R; Heng D; Tortora G; Massari F., The prospect of precision therapy for renal cell carcinoma., «CANCER TREATMENT REVIEWS», 2016, 49, pp. 37 - 44 [articolo]
Ciccarese C.; Di Nunno V.; Montironi R.; Fiorentino M.; Brunelli M.; Tortora G.; Ardizzoni A.; Massari F., The role of precision medicine for the treatment of metastatic renal cell carcinoma, «EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT», 2016, 1, pp. 369 - 377 [articolo]
Ciccarese C.; Nobili E.; Grilli D.; Casolari L.; Rihawi K.; Gelsomino F.; Tortora G.; Massari F., The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer, «EXPERT REVIEW OF ANTICANCER THERAPY», 2016, 16, pp. 681 - 696 [articolo]
Schepisi G.; Santoni M.; Massari F.; Gurioli G.; Salvi S.; Conteduca V.; Montironi R.; De Giorgi U., Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy, «BIODRUGS», 2016, 30, pp. 263 - 273 [articolo]
Ciccarese C.; Massari F.; Tortora G., 2015 and human cancer: Back to overall survival, «FUTURE ONCOLOGY», 2016, 12, pp. 1751 - 1754 [articolo]
Ciccarese C.; Massari F.; Tortora G., Acquired hemophagocytic syndrome: Comment to the case report, «FUTURE SCIENCE OA», 2015, 1, Article number: FSO31, pp. 1 - 4 [articolo]
Ciccarese C.; Ferrara R.; Fantinel E.; Zecchetto C.; Simionato F.; Grego E.; Ortolani S.; Caccese M.; Bimbatti D.; Cingarlini S.; Brunelli M.; Andreini A.; Tortora G.; Massari F., Acquired hemophagocytic syndrome in a patient with synovial sarcoma: A case report, «FUTURE SCIENCE OA», 2015, 1, Article number: FSO29, pp. 1 - 4 [articolo]
Piva F.; Santoni M.; Matrana M.R.; Satti S.; Giulietti M.; Occhipinti G.; Massari F.; Cheng L.; Lopez-Beltran A.; Scarpelli M.; Principato G.; Cascinu S.; Montironi R., BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: Molecular diagnostics and possible targets for personalized therapies, «EXPERT REVIEW OF MOLECULAR DIAGNOSTICS», 2015, 15, pp. 1201 - 1210 [articolo]
Lopez-Beltran A.; Santoni M.; Massari F.; Ciccarese C.; Tortora G.; Cheng L.; Moch H.; Scarpelli M.; Reymundo C.; Montironi R., Bladder cancer: Molecular determinants of personalized therapy, «CURRENT DRUG TARGETS», 2015, 16, pp. 115 - 124 [articolo]
Iacovelli R.; Santini D.; Rizzo M.; Felici A.; Santoni M.; Verzoni E.; Masini C.; Massari F.; Calvani N.; Mosca A.; Procopio G., Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma, «CANADIAN UROLOGICAL ASSOCIATION JOURNAL», 2015, 9, pp. 263 - 267 [articolo]
